|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q84088147
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241221010739.0 |
|
008
|
|
|
241221nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q84088147
|
|
024
|
|
|
‡a
0000-0003-0624-8819
‡2
orcid
|
|
024
|
|
|
‡a
55314524400
‡2
scopus
|
|
035
|
|
|
‡a
(OCoLC)Q84088147
|
|
100
|
0 |
|
‡a
Lígia C Gomes-da-Silva
‡c
researcher
‡9
en
|
|
400
|
0 |
|
‡a
Lígia C Gomes-da-Silva
‡c
wetenschapper
‡9
nl
|
|
670
|
|
|
‡a
Author's Cell death in photodynamic therapy: From oxidative stress to anti-tumor immunity
|
|
670
|
|
|
‡a
Author's Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology
|
|
670
|
|
|
‡a
Author's Combinatorial strategies for the induction of immunogenic cell death
|
|
670
|
|
|
‡a
Author's Corrigendum: "Combinatorial Strategies for the Induction of Immunogenic Cell Death".
|
|
670
|
|
|
‡a
Author's eIF2α phosphorylation is pathognomonic for immunogenic cell death
|
|
670
|
|
|
‡a
Author's Elimination of primary tumours and control of metastasis with rationally designed bacteriochlorin photodynamic therapy regimens
|
|
670
|
|
|
‡a
Author's Hydrogels: soft matters in photomedicine
|
|
670
|
|
|
‡a
Author's Identification of pharmacological agents that induce HMGB1 release
|
|
670
|
|
|
‡a
Author's Immune Responses after Vascular Photodynamic Therapy with Redaporfin
|
|
670
|
|
|
‡a
Author's Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells.
|
|
670
|
|
|
‡a
Author's Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges
|
|
670
|
|
|
‡a
Author's Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
|
|
670
|
|
|
‡a
Author's Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals
|
|
670
|
|
|
‡a
Author's Photodynamic therapy with redaporfin targets the endoplasmic reticulum and Golgi apparatus
|
|
670
|
|
|
‡a
Author's Pro-oxidant and Antioxidant Effects in Photodynamic Therapy: Cells Recognise that Not All Exogenous ROS Are Alike
|
|
670
|
|
|
‡a
Author's Recruitment of LC3 to damaged Golgi apparatus
|
|
670
|
|
|
‡a
Author's Redaporfin induces immunogenic cell death by selective destruction of the endoplasmic reticulum and the Golgi apparatus
|
|
670
|
|
|
‡a
Author's Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death
|
|
670
|
|
|
‡a
Author's Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
|
|
670
|
|
|
‡a
Author's Squaramide-based synthetic chloride transporters activate TFEB but block autophagic flux
|
|
670
|
|
|
‡a
Author's The oncolytic compound LTX-401 targets the Golgi apparatus
|
|
909
|
|
|
‡a
(orcid) 0000000306248819
‡9
1
|
|
909
|
|
|
‡a
(scopus) 55314524400
‡9
1
|
|
919
|
|
|
‡a
oncolyticcompoundltx401targetsthegolgiapparatus
‡A
The oncolytic compound LTX-401 targets the Golgi apparatus
‡9
1
|
|
919
|
|
|
‡a
squaramidebasedsyntheticchloridetransportersactivatetfebbutblockautophagicflux
‡A
Squaramide-based synthetic chloride transporters activate TFEB but block autophagic flux
‡9
1
|
|
919
|
|
|
‡a
simultaneousactiveintracellulardeliveryofdoxorubicinandc6ceramideshiftstheadditiveantagonisticdruginteractionofnonencapsulatedcombination
‡A
Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
‡9
1
|
|
919
|
|
|
‡a
regulatoryapprovalofphotoimmunotherapyphotodynamictherapythatinducesimmunogeniccelldeath
‡A
Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death
‡9
1
|
|
919
|
|
|
‡a
redaporfininducesimmunogeniccelldeathbyselectivedestructionoftheendoplasmicreticulumandthegolgiapparatus
‡A
Redaporfin induces immunogenic cell death by selective destruction of the endoplasmic reticulum and the Golgi apparatus
‡9
1
|
|
919
|
|
|
‡a
recruitmentoflc3todamagedgolgiapparatus
‡A
Recruitment of LC3 to damaged Golgi apparatus
‡9
1
|
|
919
|
|
|
‡a
prooxidantandantioxidanteffectsinphotodynamictherapycellsrecognisethatnotallexogenousrosarealike
‡A
Pro-oxidant and Antioxidant Effects in Photodynamic Therapy: Cells Recognise that Not All Exogenous ROS Are Alike
‡9
1
|
|
919
|
|
|
‡a
photodynamictherapywithredaporfintargetstheendoplasmicreticulumandgolgiapparatus
‡A
Photodynamic therapy with redaporfin targets the endoplasmic reticulum and Golgi apparatus
‡9
1
|
|
919
|
|
|
‡a
oncolysiswithdtt205anddtt304generatesimmunologicalmemoryincuredanimals
‡A
Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals
‡9
1
|
|
919
|
|
|
‡a
nucleolinoverexpressioninbreastcancercellsubpopulationswithdifferentstemlikephenotypeenablestargetedintracellulardeliveryofsynergisticdrugcombination
‡A
Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
‡9
1
|
|
919
|
|
|
‡a
lipidbasednanoparticlesforsirnadeliveryincancertherapyparadigmsandchallenges
‡A
Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges
‡9
1
|
|
919
|
|
|
‡a
impactofantiplk1sirnacontainingf3targetedliposomesontheviabilityofbothcancerandendothelialcells
‡A
Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells.
‡9
1
|
|
919
|
|
|
‡a
immuneresponsesaftervascularphotodynamictherapywithredaporfin
‡A
Immune Responses after Vascular Photodynamic Therapy with Redaporfin
‡9
1
|
|
919
|
|
|
‡a
identificationofpharmacologicalagentsthatinducehmgb1release
‡A
Identification of pharmacological agents that induce HMGB1 release
‡9
1
|
|
919
|
|
|
‡a
hydrogelssoftmattersinphotomedicine
‡A
Hydrogels: soft matters in photomedicine
‡9
1
|
|
919
|
|
|
‡a
eliminationofprimarytumoursandcontrolofmetastasiswithrationallydesignedbacteriochlorinphotodynamictherapyregimens
‡A
Elimination of primary tumours and control of metastasis with rationally designed bacteriochlorin photodynamic therapy regimens
‡9
1
|
|
919
|
|
|
‡a
eif2αphosphorylationispathognomonicforimmunogeniccelldeath
‡A
eIF2α phosphorylation is pathognomonic for immunogenic cell death
‡9
1
|
|
919
|
|
|
‡a
corrigendumcombinatorialstrategiesfortheinductionofimmunogeniccelldeath
‡A
Corrigendum: "Combinatorial Strategies for the Induction of Immunogenic Cell Death".
‡9
1
|
|
919
|
|
|
‡a
combinatorialstrategiesfortheinductionofimmunogeniccelldeath
‡A
Combinatorial strategies for the induction of immunogenic cell death
‡9
1
|
|
919
|
|
|
‡a
challengingthefutureofsirnatherapeuticsagainstcancerthecrucialroleofnanotechnology
‡A
Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology
‡9
1
|
|
919
|
|
|
‡a
celldeathinphotodynamictherapyfromoxidativestresstoantitumorimmunity
‡A
Cell death in photodynamic therapy: From oxidative stress to anti-tumor immunity
‡9
1
|
|
996
|
|
|
‡2
PTBNP|1695276
|
|
996
|
|
|
‡2
PTBNP|976694
|
|
996
|
|
|
‡2
ISNI|0000000109046222
|
|
996
|
|
|
‡2
BNF|14063593
|
|
996
|
|
|
‡2
LC|n 2024244466
|
|
996
|
|
|
‡2
PTBNP|184837
|
|
996
|
|
|
‡2
PTBNP|248975
|
|
996
|
|
|
‡2
ISNI|0000000070326015
|
|
996
|
|
|
‡2
LC|no2015004748
|
|
996
|
|
|
‡2
PTBNP|1709981
|
|
996
|
|
|
‡2
ISNI|0000000081451049
|
|
996
|
|
|
‡2
ISNI|0000000036775298
|
|
996
|
|
|
‡2
PTBNP|1511267
|
|
996
|
|
|
‡2
ISNI|000000007793366X
|
|
996
|
|
|
‡2
PTBNP|1406374
|
|
996
|
|
|
‡2
BLBNB|000370659
|
|
996
|
|
|
‡2
SUDOC|241164877
|
|
996
|
|
|
‡2
BLBNB|000546923
|
|
996
|
|
|
‡2
DNB|1050223861
|
|
996
|
|
|
‡2
ISNI|0000000040599434
|
|
996
|
|
|
‡2
ISNI|0000000069690389
|
|
996
|
|
|
‡2
LC|n 2019252016
|
|
996
|
|
|
‡2
BLBNB|000353787
|
|
996
|
|
|
‡2
BIBSYS|11029994
|
|
996
|
|
|
‡2
PTBNP|242260
|
|
996
|
|
|
‡2
PTBNP|83588
|
|
996
|
|
|
‡2
PTBNP|1754143
|
|
996
|
|
|
‡2
BLBNB|001129607
|
|
996
|
|
|
‡2
DNB|1057167150
|
|
996
|
|
|
‡2
ISNI|0000000067823344
|
|
996
|
|
|
‡2
ISNI|0000000068823178
|
|
996
|
|
|
‡2
LC|n 2024253100
|
|
996
|
|
|
‡2
SUDOC|126284512
|
|
996
|
|
|
‡2
PTBNP|1394926
|
|
996
|
|
|
‡2
BNE|XX1388733
|
|
996
|
|
|
‡2
ISNI|0000000054996772
|
|
996
|
|
|
‡2
PTBNP|1626035
|
|
996
|
|
|
‡2
SUDOC|073444715
|
|
996
|
|
|
‡2
ISNI|0000000083972235
|
|
996
|
|
|
‡2
LC|no2009017047
|
|
996
|
|
|
‡2
LC|n 89283659
|
|
996
|
|
|
‡2
SUDOC|168237911
|
|
996
|
|
|
‡2
LC|n 2005177423
|
|
996
|
|
|
‡2
ISNI|0000000069407686
|
|
996
|
|
|
‡2
PTBNP|1438137
|
|
996
|
|
|
‡2
ISNI|0000000073205251
|
|
996
|
|
|
‡2
PTBNP|1427248
|
|
996
|
|
|
‡2
LC|n 2016257115
|
|
996
|
|
|
‡2
DNB|115736085
|
|
996
|
|
|
‡2
BLBNB|000560507
|
|
996
|
|
|
‡2
ISNI|0000000033189963
|
|
996
|
|
|
‡2
ISNI|0000000103258849
|
|
996
|
|
|
‡2
DNB|1283603861
|
|
996
|
|
|
‡2
ISNI|0000000496715106
|
|
996
|
|
|
‡2
LC|n 85099093
|
|
996
|
|
|
‡2
LC|no2023003916
|
|
996
|
|
|
‡2
BLBNB|000399261
|
|
996
|
|
|
‡2
BLBNB|000467563
|
|
996
|
|
|
‡2
ISNI|000000049656757X
|
|
996
|
|
|
‡2
ISNI|0000000069407897
|
|
996
|
|
|
‡2
BLBNB|001582147
|
|
996
|
|
|
‡2
BLBNB|000444046
|
|
996
|
|
|
‡2
BLBNB|001457358
|
|
996
|
|
|
‡2
ISNI|0000000024180262
|
|
996
|
|
|
‡2
PTBNP|186707
|
|
996
|
|
|
‡2
ISNI|000000039084177X
|
|
996
|
|
|
‡2
ISNI|0000000047078885
|
|
996
|
|
|
‡2
BLBNB|000575940
|
|
996
|
|
|
‡2
PTBNP|46911
|
|
996
|
|
|
‡2
SUDOC|080657958
|
|
996
|
|
|
‡2
PTBNP|116854
|
|
996
|
|
|
‡2
LC|n 2005177468
|
|
996
|
|
|
‡2
DNB|116789801X
|
|
996
|
|
|
‡2
LC|nb2017020841
|
|
996
|
|
|
‡2
BNC|981058512081006706
|
|
996
|
|
|
‡2
BLBNB|000450707
|
|
996
|
|
|
‡2
PTBNP|973675
|
|
996
|
|
|
‡2
ISNI|0000000070998866
|
|
996
|
|
|
‡2
SUDOC|264997743
|
|
996
|
|
|
‡2
BLBNB|000353948
|
|
996
|
|
|
‡2
ISNI|0000000073268826
|
|
996
|
|
|
‡2
ISNI|000000006932774X
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
